GALT

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company developing therapies for the treatment of fibrotic liver disease and cancer. The company's lead drug candidate, belapectin, is a galectin-3 inhibitor being evaluated in clinical trials for cirrhosis and nonalcoholic steatohepatitis (NASH) with advanced fibrosis. Galectin Therapeutics is also exploring applications in cancer treatment, where galectin-3 plays a role in tumor progression and metastasis. The company is headquartered in Norcross, Georgia, and focuses on addressing significant unmet medical needs in liver diseases.